Almirall’s Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis | BioSpace

BARCELONA, Spain–(BUSINESS WIRE)– Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the…

Quelle: www.biospace.com via Google News

Schreibe einen Kommentar